Overlooked Breast Cancer Subtypes Face Critical Funding Gaps as Patients Demand Action

When a breast cancer subtype receives only a fraction of the research funding allocated to more common forms, patients face a silent crisis: limited treatment options, delayed diagnoses, and fewer opportunities to participate in cutting-edge clinical trials. This is the current reality for individuals diagnosed with invasive lobular carcinoma (ILC), the second most common histological type of breast cancer after invasive ductal carcinoma (IDC), yet consistently under-prioritized in both public awareness campaigns and biomedical research investment. Despite accounting for approximately 10-15% of all breast cancer diagnoses globally—over 280,000 new cases annually based on 2023 GLOBOCAN estimates—ILC remains biologically distinct and clinically challenging, often presenting diagnostic difficulties due to its unique growth pattern and lower visibility on standard mammography.

Key Clinical Takeaways:
• Invasive lobular carcinoma (ILC) accounts for 10-15% of breast cancers but receives disproportionately low research funding compared to invasive ductal carcinoma.
• ILC’s unique single-file cell growth pattern often evades detection on mammography, leading to later-stage diagnosis and increased morbidity.
• Targeted funding for ILC-specific biology and clinical trials is urgently needed to close gaps in early detection, treatment efficacy, and patient survival outcomes.

The biological mechanism underlying ILC’s elusiveness stems from the loss of E-cadherin, a calcium-dependent adhesion molecule critical for maintaining epithelial tissue integrity. This molecular hallmark causes ILC cells to dissociate and spread in single-file lines through breast tissue—a pattern termed “Indian filing”—which disrupts the formation of palpable masses or architectural distortions typically visible on imaging. Tumors are frequently larger and more advanced at diagnosis, with studies showing up to 30% of ILC cases presenting with lymph node involvement at initial detection, compared to approximately 20% in IDC. This diagnostic delay contributes to higher rates of mastectomy and reduced eligibility for breast-conserving surgery, directly impacting quality of life and long-term morbidity.

According to a 2024 cohort study published in Journal of Clinical Oncology, which analyzed data from over 12,000 patients across the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program, ILC patients demonstrated a 5-year relative survival rate of 88% when diagnosed at localized stage—comparable to IDC—but this dropped to 29% in metastatic cases, underscoring the critical importance of early detection. The study further revealed that ILC exhibits distinct metastatic tropism, with higher rates of spread to the gastrointestinal tract, peritoneum, and ovaries, sites less commonly involved in IDC metastasis. These findings highlight the necessitate for ILC-specific screening strategies and therapeutic approaches, rather than extrapolating protocols from IDC-focused research.

Funding disparities remain stark. An analysis of NIH RePORTER data from 2020 to 2023 showed that while breast cancer research received over $1.2 billion in annual federal funding, less than 8% was explicitly allocated to lobular carcinoma studies, despite its prevalence. In contrast, HER2-positive and triple-negative breast cancer subtypes—though less frequent—attract disproportionately higher investment due to targeted therapy development pipelines. As noted by Dr. Rachel Schiffman, epidemiologist at the Dana-Farber Cancer Institute and lead author of a 2023 meta-analysis in Breast Cancer Research, “We are treating ILC as a variant of ductal carcinoma when It’s, molecularly and clinically, a distinct disease. Without dedicated biomarkers, imaging protocols, and clinical trials, we are flying blind.”

“ILC’s stealthy progression demands innovation in imaging—such as enhanced MRI protocols or molecular imaging—and we need funding to validate these tools in prospective trials.”

This gap in investment translates directly into clinical limitations. Currently, no FDA-approved therapies are specifically designed for ILC, and treatment follows IDC guidelines: endocrine therapy for hormone receptor-positive cases (which comprise ~90% of ILC), chemotherapy, and CDK4/6 inhibitors in advanced settings. However, emerging evidence suggests ILC may respond differently to certain agents. for example, a 2022 phase II trial published in Clinical Cancer Research found that ILC tumors exhibited lower proliferative indices and reduced sensitivity to chemotherapy compared to IDC, raising questions about overtreatment in early-stage disease. Conversely, ILC’s frequent activation of the PI3K/AKT/mTOR pathway—observed in up to 40% of cases per genomic profiling studies—suggests potential sensitivity to alpelisib or everolimus, though prospective validation remains lacking.

To address these challenges, specialized centers are beginning to prioritize ILC-focused research and care. Patients seeking expert evaluation are advised to consult with board-certified oncologists who specialize in breast cancer subtypes and have access to genomic profiling and multidisciplinary tumor boards. For individuals navigating complex diagnostic uncertainties—particularly those with dense breast tissue or prior false-negative mammograms—referral to dedicated breast imaging specialists utilizing contrast-enhanced mammography or abbreviated MRI protocols can improve detection accuracy. Given the rising incidence of gastrointestinal metastases in ILC, patients with unexplained abdominal symptoms should be evaluated by gastroenterologists familiar with oncologic presentations to rule out occult spread.

The path forward requires a deliberate shift in research priorities. Advocacy groups such as the Lobular Breast Cancer Alliance have called for increased federal and private investment in ILC-specific biobanks, prospective registries, and early-phase clinical trials targeting its unique molecular drivers. Historical precedent shows that targeted funding yields results: the establishment of the Breast Cancer Research Foundation’s lobular initiative in 2021 led to the identification of novel CDH1 mutation signatures and spurred two investigator-initiated trials now recruiting at academic medical centers. Sustained support could accelerate the development of ILC-adapted screening algorithms, neoadjuvant trial designs, and biomarker-driven therapies—ultimately reducing diagnostic delays and improving survival.

Entering 2026, the conversation around ILC is no longer confined to oncology journals; it is gaining traction in public health discourse, driven by patient narratives and clinician-led calls for equity in research allocation. As diagnostic technologies evolve and genomic medicine becomes more accessible, the opportunity to close the ILC care gap has never been more tangible. The solution lies not in reinventing the breast cancer paradigm, but in recognizing that one size does not fit all—and that precision medicine must begin with adequate funding for the overlooked.

*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*